Jon Lenn, Chief Scientific Officer, MedPharm, has direct responsibility for the company’s global scientific operations. Since joining in 2015, he has led MedPharm’s development of cutting-edge performance models for
assessing the penetration and activity of clients’ products targeted towards key biochemical pathways. He has played a critical role in MedPharm’s growth, as well as the development and success of the US facility.

Dr Lenn has more than 15 years’ experience in developing dermatological projects with Connetics, which was acquired by Stiefel, itself subsequently acquired by GSK, and has been directly involved with the development and
approval of eight products. He received his PhD on the topical delivery of macromolecules from the University of Reading, UK.

More contributions